p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer
Jie Luo,Zhixiang Chen,Yuanyuan Qiao,Jean Ching-Yi Tien,Eleanor Young,Rahul Mannan,Somnath Mahapatra,Tongchen He,Sanjana Eyunni,Yuping Zhang,Yang Zheng,Fengyun Su,Xuhong Cao,Rui Wang,Yunhui Cheng,Rithvik Seri,James George,Miriam Shahine,Stephanie J. Miner,Ulka Vaishampayan,Mi Wang,Shaomeng Wang,Abhijit Parolia,Arul M. Chinnaiyan
DOI: https://doi.org/10.1101/2024.03.29.587346
2024-05-24
Abstract:Prostate cancer is an exemplar of an enhancer-binding transcription factor-driven disease. The androgen receptor (AR) enhanceosome complex comprised of chromatin and epigenetic coregulators assembles at enhancer elements to drive disease progression. The paralog lysine acetyltransferases p300 and CBP deposit histone marks that are associated with enhancer activation. Here, we demonstrate that p300/CBP are determinant cofactors of the active AR enhanceosome in prostate cancer. Histone H2B N-terminus multisite lysine acetylation (H2BNTac), which is exclusively reliant on p300/CBP catalytic function, marked active enhancers and was notably elevated in prostate cancer lesions relative to the adjacent benign epithelia. Degradation of p300/CBP rapidly depleted acetylation marks associated with the active AR enhanceosome, which was only partially phenocopied by inhibition of their reader bromodomains. Notably, H2BNTac was effectively abrogated only upon p300/CBP degradation, which led to a stronger suppression of p300/CBP-dependent oncogenic gene programs relative to bromodomain inhibition or the inhibition of its catalytic domain. In vivo experiments using an orally active p300/CBP proteolysis targeting chimera (PROTAC) degrader (CBPD-409) showed that p300/CBP degradation potently inhibited tumor growth in preclinical models of castration-resistant prostate cancer and synergized with AR antagonists. While mouse p300/CBP orthologs were effectively degraded in host tissues, prolonged treatment with the PROTAC degrader was well tolerated with no significant signs of toxicity. Taken together, our study highlights the pivotal role of p300/CBP in maintaining the active AR enhanceosome and demonstrates how target degradation may have functionally distinct effects relative to target inhibition, thus supporting the development of p300/CBP degraders for the treatment of advanced prostate cancer.
Cancer Biology